Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Injuries | 3 | 2014 | 268 | 0.780 |
Why?
|
| Peroxiredoxin VI | 1 | 2014 | 18 | 0.490 |
Why?
|
| Head Protective Devices | 1 | 2011 | 15 | 0.400 |
Why?
|
| Recovery of Function | 1 | 2014 | 506 | 0.380 |
Why?
|
| Hospitalization | 2 | 2017 | 977 | 0.360 |
Why?
|
| Oxidative Stress | 1 | 2014 | 718 | 0.360 |
Why?
|
| Sepsis | 4 | 2014 | 233 | 0.270 |
Why?
|
| HIV-1 | 5 | 1999 | 177 | 0.270 |
Why?
|
| Program Development | 1 | 2007 | 240 | 0.270 |
Why?
|
| Emergency Service, Hospital | 3 | 2014 | 711 | 0.270 |
Why?
|
| Mass Screening | 2 | 2008 | 837 | 0.250 |
Why?
|
| RNA, Viral | 5 | 1999 | 93 | 0.240 |
Why?
|
| Craniocerebral Trauma | 2 | 2014 | 50 | 0.230 |
Why?
|
| Chemokine CXCL12 | 2 | 2014 | 51 | 0.220 |
Why?
|
| RNA Splicing | 3 | 1999 | 32 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 772 | 0.210 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 3 | 1999 | 43 | 0.200 |
Why?
|
| Child Abuse | 2 | 2014 | 186 | 0.200 |
Why?
|
| Arrestins | 2 | 2011 | 92 | 0.180 |
Why?
|
| HIV Infections | 1 | 2007 | 775 | 0.170 |
Why?
|
| Genes, Viral | 1 | 1997 | 44 | 0.160 |
Why?
|
| Skull Fractures | 1 | 2017 | 17 | 0.160 |
Why?
|
| Endotoxemia | 3 | 2012 | 27 | 0.150 |
Why?
|
| Stethoscopes | 1 | 2017 | 4 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2012 | 626 | 0.150 |
Why?
|
| Diabetes Complications | 1 | 2018 | 249 | 0.140 |
Why?
|
| Alloys | 1 | 2017 | 66 | 0.140 |
Why?
|
| Logistic Models | 3 | 2017 | 1419 | 0.140 |
Why?
|
| Interleukin-6 | 3 | 2012 | 330 | 0.140 |
Why?
|
| Disinfection | 1 | 2017 | 112 | 0.140 |
Why?
|
| GTP-Binding Protein alpha Subunit, Gi2 | 2 | 2012 | 15 | 0.140 |
Why?
|
| Copper | 1 | 2017 | 149 | 0.130 |
Why?
|
| Child, Preschool | 4 | 2017 | 3185 | 0.130 |
Why?
|
| Lipopolysaccharides | 3 | 2012 | 455 | 0.130 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2014 | 21 | 0.120 |
Why?
|
| Length of Stay | 1 | 2017 | 780 | 0.120 |
Why?
|
| Gene Products, rev | 4 | 1999 | 8 | 0.120 |
Why?
|
| Alkaline Ceramidase | 1 | 2014 | 35 | 0.120 |
Why?
|
| Incidence | 3 | 2014 | 1582 | 0.120 |
Why?
|
| South Carolina | 4 | 2017 | 2750 | 0.110 |
Why?
|
| Cause of Death | 1 | 2014 | 241 | 0.110 |
Why?
|
| Prognosis | 3 | 2015 | 2093 | 0.110 |
Why?
|
| Gene Expression Regulation, Viral | 3 | 1999 | 38 | 0.110 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2012 | 34 | 0.110 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 567 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 234 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 290 | 0.110 |
Why?
|
| Multiple Organ Failure | 1 | 2012 | 36 | 0.100 |
Why?
|
| Sphingosine | 1 | 2014 | 315 | 0.100 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2012 | 114 | 0.100 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 48 | 0.100 |
Why?
|
| Survival Rate | 2 | 2014 | 1055 | 0.100 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2012 | 34 | 0.100 |
Why?
|
| Humans | 17 | 2018 | 68525 | 0.100 |
Why?
|
| Biomarkers | 2 | 2014 | 1593 | 0.100 |
Why?
|
| Arthritis, Experimental | 1 | 2011 | 38 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2014 | 384 | 0.100 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2011 | 47 | 0.100 |
Why?
|
| Obesity | 1 | 2018 | 1074 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 929 | 0.100 |
Why?
|
| Research Design | 1 | 2015 | 729 | 0.090 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 155 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 1026 | 0.090 |
Why?
|
| Mitochondria | 1 | 2014 | 643 | 0.080 |
Why?
|
| Mice | 7 | 2014 | 8472 | 0.080 |
Why?
|
| Male | 9 | 2018 | 37281 | 0.080 |
Why?
|
| Interleukin-10 | 3 | 2014 | 144 | 0.080 |
Why?
|
| Mice, Knockout | 4 | 2014 | 1692 | 0.080 |
Why?
|
| Inflammation | 2 | 2011 | 1030 | 0.070 |
Why?
|
| Animals | 10 | 2014 | 20877 | 0.070 |
Why?
|
| Continuity of Patient Care | 1 | 2007 | 170 | 0.070 |
Why?
|
| Stroke | 1 | 2018 | 2161 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 503 | 0.060 |
Why?
|
| Infant | 3 | 2017 | 2891 | 0.060 |
Why?
|
| Female | 6 | 2018 | 38015 | 0.060 |
Why?
|
| Base Sequence | 4 | 1999 | 1015 | 0.060 |
Why?
|
| Brain | 1 | 2014 | 2175 | 0.060 |
Why?
|
| Cytoplasm | 3 | 1999 | 155 | 0.060 |
Why?
|
| Young Adult | 1 | 2014 | 5708 | 0.050 |
Why?
|
| Aged | 2 | 2018 | 14842 | 0.050 |
Why?
|
| Cell Line | 4 | 2012 | 1752 | 0.050 |
Why?
|
| Population Surveillance | 2 | 2014 | 285 | 0.050 |
Why?
|
| Macrophages, Peritoneal | 2 | 2012 | 67 | 0.050 |
Why?
|
| Genes, rev | 2 | 1998 | 4 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 791 | 0.050 |
Why?
|
| Adolescent | 1 | 2014 | 8903 | 0.050 |
Why?
|
| beta-Arrestin 2 | 2 | 2011 | 29 | 0.050 |
Why?
|
| COS Cells | 2 | 1999 | 155 | 0.050 |
Why?
|
| beta-Arrestins | 2 | 2011 | 80 | 0.050 |
Why?
|
| Peroxidase | 2 | 2011 | 40 | 0.050 |
Why?
|
| Cecum | 2 | 2011 | 39 | 0.050 |
Why?
|
| Introns | 2 | 1997 | 68 | 0.050 |
Why?
|
| Middle Aged | 2 | 2018 | 21119 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2017 | 2356 | 0.050 |
Why?
|
| Spleen | 2 | 2011 | 301 | 0.040 |
Why?
|
| Child | 1 | 2011 | 6400 | 0.040 |
Why?
|
| Alcoholism | 1 | 2008 | 1109 | 0.040 |
Why?
|
| United States | 2 | 2014 | 7335 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 1032 | 0.040 |
Why?
|
| Risk Factors | 3 | 2017 | 5719 | 0.040 |
Why?
|
| Transfection | 2 | 1998 | 782 | 0.040 |
Why?
|
| Ribonucleoproteins | 1 | 1998 | 19 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2017 | 7264 | 0.040 |
Why?
|
| Genes, tat | 1 | 1997 | 2 | 0.040 |
Why?
|
| Proviruses | 1 | 1997 | 8 | 0.040 |
Why?
|
| Genome, Viral | 1 | 1997 | 14 | 0.040 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 4 | 1999 | 8 | 0.040 |
Why?
|
| Sequence Deletion | 1 | 1997 | 89 | 0.040 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2017 | 6 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2014 | 2453 | 0.040 |
Why?
|
| Macrophages | 2 | 2012 | 647 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1997 | 204 | 0.040 |
Why?
|
| DNA Primers | 1 | 1997 | 302 | 0.040 |
Why?
|
| Gram-Negative Bacteria | 1 | 2017 | 55 | 0.040 |
Why?
|
| Fibroblasts | 2 | 2012 | 902 | 0.040 |
Why?
|
| Equipment Contamination | 1 | 2017 | 38 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 2017 | 77 | 0.040 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 92 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 880 | 0.030 |
Why?
|
| Adult | 1 | 2014 | 21375 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2017 | 294 | 0.030 |
Why?
|
| Cross Infection | 1 | 2017 | 195 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2012 | 2790 | 0.030 |
Why?
|
| Electron Transport Complex IV | 1 | 2014 | 33 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 730 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2014 | 65 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 848 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 2550 | 0.030 |
Why?
|
| Stroke Rehabilitation | 1 | 2018 | 334 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2014 | 242 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 272 | 0.030 |
Why?
|
| Retinal Hemorrhage | 1 | 2013 | 7 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 319 | 0.030 |
Why?
|
| Lipopeptides | 1 | 2012 | 7 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2013 | 84 | 0.030 |
Why?
|
| Poly I-C | 1 | 2012 | 20 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2014 | 197 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 536 | 0.030 |
Why?
|
| Stem Cells | 1 | 2014 | 248 | 0.030 |
Why?
|
| Intracranial Hemorrhages | 1 | 2013 | 80 | 0.030 |
Why?
|
| RNA-Binding Proteins | 1 | 1994 | 215 | 0.030 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2014 | 200 | 0.030 |
Why?
|
| Zymosan | 1 | 2012 | 12 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2014 | 384 | 0.030 |
Why?
|
| beta-Arrestin 1 | 1 | 2011 | 22 | 0.030 |
Why?
|
| Peptides | 2 | 2011 | 455 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 951 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 546 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2011 | 120 | 0.030 |
Why?
|
| Wasp Venoms | 1 | 2011 | 8 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2015 | 705 | 0.020 |
Why?
|
| Bacterial Load | 1 | 2011 | 24 | 0.020 |
Why?
|
| Pertussis Toxin | 1 | 2011 | 72 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2011 | 41 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 209 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 246 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 2010 | 25 | 0.020 |
Why?
|
| Blood | 1 | 2010 | 40 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 146 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 1999 | 1446 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 235 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 4655 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1139 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2014 | 447 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 954 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 3702 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1194 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 714 | 0.020 |
Why?
|
| Gene Products, gag | 2 | 1999 | 11 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 2004 | 0.020 |
Why?
|
| Cytokines | 1 | 2011 | 866 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2010 | 595 | 0.020 |
Why?
|
| Lung | 1 | 2010 | 849 | 0.020 |
Why?
|
| Liver | 1 | 2010 | 1118 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1753 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 1609 | 0.010 |
Why?
|
| Mutation | 2 | 1999 | 1213 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 7028 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1996 | 1663 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 2798 | 0.010 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 1998 | 7 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1998 | 144 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 1998 | 337 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1998 | 305 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 710 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 1998 | 271 | 0.010 |
Why?
|
| Genes, nef | 1 | 1996 | 1 | 0.010 |
Why?
|
| Fusion Proteins, gag-pol | 1 | 1996 | 2 | 0.010 |
Why?
|
| Gene Products, env | 1 | 1996 | 3 | 0.010 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 1996 | 2 | 0.010 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 1996 | 5 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1996 | 35 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1996 | 100 | 0.010 |
Why?
|
| Exons | 1 | 1996 | 122 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1996 | 420 | 0.010 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 1994 | 4 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1994 | 35 | 0.010 |
Why?
|
| Binding Sites | 1 | 1996 | 631 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1994 | 181 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1994 | 765 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 1082 | 0.010 |
Why?
|